Dipeptide and pharmaceutical composition containing same

Specific D-amino acid dipeptides, indigestible and long-lasting in the bloodstream, address the lack of clarity in liver hydrolyzate compositions by effectively preventing and improving fatigue through pharmaceutical and food applications.

JP7584109B2Active Publication Date: 2024-11-15ZERIA PHARMA +1
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2023067139
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-04-26
Filing Date
2023-04-17
Publication Date
2024-11-15
Estimated Expiration
2039-04-25

AI Technical Summary

Technical Problem

Existing compositions for addressing chronic fatigue, such as liver hydrolyzate, lack clarity on active ingredients, and there is a need for a component that effectively prevents and improves fatigue.

Method used

Development of specific dipeptides derived from D-amino acids, which are indigestible and remain in the bloodstream for a prolonged period, offering fatigue prevention and improvement effects.

Benefits of technology

The identified dipeptides, particularly those in the β-form, exhibit excellent anti-fatigue properties, enhancing motor function, reducing fatigue, and providing sustainability through oral administration in pharmaceutical and food compositions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584109000002
    Figure 0007584109000002
  • Figure 0007584109000003
    Figure 0007584109000003
  • Figure 0007584109000004
    Figure 0007584109000004
Patent Text Reader

Abstract

To provide a novel ingredient having an action of preventing and improving fatigue, and a pharmaceutical composition or food composition comprising the ingredient.SOLUTION: Provided are a dipeptide selected from (D)Asp-(D)Leu, (D)Asp-(D)Val, (D)Asp-(D)Phe, (D)Asp-(D)Ile, and (D)Asp-(L)Leu, (D) Asp-(L)Val, (D)Asp-(L)Phe, and (D)Asp-(L)Ile; and a pharmaceutical composition comprising the dipeptide.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a dipeptide and a pharmaceutical or food composition containing the same. [Background technology]

[0002] Fatigue generally has the main symptoms of tiredness and malaise, and can result in decreased athletic ability, sleep disorders, decreased motivation, etc. Short-term fatigue can be cured by resting, sleeping, taking in nutrients, etc., but chronic fatigue is difficult to cure due to long-term general fatigue, malaise, slight fever, etc.

[0003] It is known that amino acid compositions (Patent Document 1), L-carnitine (Patent Document 2), ascorbic acid, etc. (Patent Document 3) are useful for treating fatigue. In addition, it has been reported that liver hydrolysates have an AMPK activating effect and have anti-fatigue effects (Patent Document 4). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Publication No. 9-124473 [Patent Document 2] JP 2001-046021 A [Patent Document 3] Japanese Patent Application Publication No. 6-327435 [Patent Document 4] International Publication No. 2015 / 022927 Summary of the Invention [Problem to be solved by the invention]

[0005] Although liver hydrolysate is said to contain a large amount of amino acids and peptides, the actual active ingredients have not been identified. Therefore, an object of the present invention is to provide a novel component having the effect of preventing and improving fatigue. [Means for solving the problem]

[0006] The present inventors therefore conducted studies to develop a new agent for preventing and improving fatigue, and by administering liver hydrolysates to animals, they searched for indigestible peptides that are transferred into the bloodstream. They also fractionated the peptides from the liver hydrolysates using various columns and evaluated their pharmacological effects. As a result, they discovered a dipeptide derived not from L-amino acids but from a specific D-amino acid, and found that this dipeptide has the effect of preventing and improving fatigue, thereby completing the present invention.

[0007] That is, the present invention provides the following [1] to [9].

[0008] [1] (D)Ile-(D)Pro, (D)Leu-(D)Pro, (D)Pro-(D)Ile, (D)Pro-(D)Leu, (D)Val-(D)-Pro, (D)Pro-(D)Val, (D)Leu- (D)Hyp, (D)Ile-(D)Hyp, (D)Val-(D)Hyp, (D)Asp-(D)Ile, (D)Asp-(D)Val, (D)Asp-(D)Leu, (D)Asp-(D)Phe, (D)Il e-(L)Pro, (D)Leu-(L)Pro, (D)Pro-(L)Ile, (D)Pro-(L)Leu, (D)Val-(L)-Pro, (D)Pro-(L)Val, (D)Leu-(L)Hyp, ( A dipeptide selected from D)Ile-(L)Hyp, (D)Val-(L)Hyp, (D)Asp-(L)Ile, (D)Asp-(L)Val, (D)Asp-(L)Leu, and (D)Asp-(L)Phe. [2] The dipeptide according to [1], which is selected from (D)Asp-(D)Val, (D)Asp-(D)Ile, (D)Asp-(D)Leu, (D)Asp-(D)Phe, (D)Asp-(L)Val, (D)Asp-(L)Ile, (D)Asp-(L)Leu, and (D)Asp-(L)Phe. [3] A pharmaceutical composition comprising the dipeptide according to [1] or [2]. [4] The pharmaceutical composition according to [3], which is an agent for preventing and improving fatigue. [5] A food composition containing the dipeptide according to [1] or [2]. [6] The food composition according to [5], which is a food composition for preventing and improving fatigue. [7] Use of the dipeptide according to [1] or [2] for the manufacture of a fatigue prevention / improvement agent or a food for preventing / improving fatigue. [8] The dipeptide according to [1] or [2] for preventing and improving fatigue. [9] A method for preventing and improving fatigue, comprising administering an effective amount of the dipeptide described in [1] or [2]. Effect of the Invention

[0009] The dipeptide of the present invention is derived from D-amino acids and is therefore indigestible, persists in the blood for a long time, and has the effect of preventing and improving fatigue, and is therefore useful as a pharmaceutical or food composition for preventing and improving fatigue. [Brief description of the drawings]

[0010] [Figure 1] 1 shows the anti-fatigue effect of the hydrophobic peptide fraction. [Diagram 2] 1 shows the anti-fatigue effect of a hydrophobic pyroglutamyl peptide fraction. [Diagram 3] 1 shows the anti-fatigue effect of the hydrophilic peptide fraction. [Figure 4] 1 shows the anti-fatigue effect of a hydrophilic pyroglutamyl peptide fraction. [Diagram 5] The anti-fatigue effect of Asp-Leu(Dα) is shown. [Figure 6] 1 shows the anti-fatigue effect of Asp-Leu(Dβ). [Figure 7] 1 shows the anti-fatigue effect of Asp-Val(Dα). [Figure 8] 1 shows the anti-fatigue effect of Asp-Val(Dβ). [Figure 9] The anti-fatigue effect of Asp-Phe(Dα) is shown. [Figure 10] The anti-fatigue effect of Asp-Phe(Dβ) is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The dipeptides of the present invention include (D)Ile-(D)Pro, (D)Leu-(D)Pro, (D)Pro-(D)Ile, (D)Pro-(D)Leu, (D)Val- (D)-Pro, (D)Pro-(D)Val, (D)Leu-(D)Hyp, (D)Ile-(D)Hyp, (D)Val-(D)Hyp, (D)Asp-(D) Ile, (D)Asp-(D)Val, (D)Asp-(D)Leu, (D)Asp-(D)Phe, (D)Ile-(L)Pro, (D)Leu-(L)Pro, (D)Pro-(L)Ile, (D)Pro-(L)Leu, (D)Val-(L)-Pro, (D)Pro-(L)Val, (D)Leu-(L)Hyp, (D)I The dipeptide is selected from Le-(L)Hyp, (D)Val-(L)Hyp, (D)Asp-(L)Ile, (D)Asp-(L)Val, (D)Asp-(L)Leu, and (D)Asp-(L)Phe. Among these, from the viewpoints of transfer into the blood upon oral administration, duration of action, and anti-fatigue effect, dipeptides selected from (D)Asp-(D)Val, (D)Asp-(D)Ile, (D)Asp-(D)Leu, (D)Asp-(D)Phe, (D)Asp-(L)Val, (D)Asp-(L)Ile, (D)Asp-(L)Leu, and (D)Asp-(L)Phe are preferred, with (D)Asp-(D)Leu and (D)Asp-(L)Leu being more preferred. Here, the designation (D) means that the amino acid is in the D-form, and the designation (L) means that the amino acid is in the L-form. Of the α- and β-forms of the (D)- or (L)-dipeptides, the β-form is more preferred.

[0012] The dipeptide of the present invention can be produced by a conventional liquid phase peptide synthesis method or solid phase peptide synthesis method using (D) an amino acid as a raw material. For example, it can be produced by condensing an amino acid in which functional groups other than the α-amino group are protected with an amino acid in which functional groups other than the carboxy group are protected or an amino acid in which the carboxy group has been activated and functional groups other than the carboxy group are protected, and then removing the protecting groups. Here, examples of the protecting group for the amino group of the amino acid include a benzyloxycarbonyl group, a tert-butoxycarbonyl group, a fluorenylmethoxycarbonyl group, etc. Examples of the protecting group for the carboxy group include a tert-butyl group, a benzyl group, etc. The condensation reaction can be carried out using a method using a condensing agent such as N,N'-dicyclohexylcarbodiimide, dicyclohexylurea, or the like, an active ester method such as nitrophenol, N-hydroxysuccinimide, or the like, a mixed acid anhydride method, or the like. After the condensation reaction is completed, the protecting group is removed, and in the case of the solid phase method, the bond between the C-terminus of the peptide and the resin is further cleaved. Furthermore, the peptide of the present invention is purified according to a conventional method.

[0013] The dipeptide of the present invention may be an acid addition salt or a base salt. Examples of the acid addition salt include inorganic acid salts such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, and perchloric acid, and organic acid salts such as citric acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid, and trifluoroacetic acid. Examples of the base salt include alkali metal salts such as sodium, potassium, and lithium, and alkaline earth metal salts such as calcium and magnesium.

[0014] The peptides of the present invention may be solvated. Examples of the solvate include solvates of water (in the case of hydrates), methanol, ethanol, isopropanol, and the like.

[0015] The dipeptide of the present invention is indigestible, has high blood transmigration after oral administration, has excellent long-lasting effects, and has a fatigue prevention and improvement effect. Here, examples of the fatigue prevention and improvement effect include motor function maintenance effect, motor function improvement effect, anti-fatigue effect, anti-stress effect, fatigue feeling reduction effect, chronic fatigue prevention effect, fatigue recovery effect, palpitations prevention and improvement effect, wakefulness prevention and improvement effect, shortness of breath prevention and improvement effect, and muscle pain prevention and improvement effect. Therefore, a composition containing the dipeptide of the present invention is useful as a pharmaceutical composition or a food composition.

[0016] The pharmaceutical composition of the present invention can be administered orally, transdermally, enterally, intravenously, etc., but is more preferably administered orally. Examples of preparations for oral administration include liquids, tablets, powders, fine granules, granules, capsules, etc., but liquids and tablets are preferred, and liquids are more preferred.

[0017] To prepare these oral preparations, excipients such as lactose, mannitol, corn starch, crystalline cellulose, etc., binders such as cellulose derivatives, gum arabic, gelatin, etc., disintegrants such as calcium carboxymethylcellulose, lubricants such as talc, magnesium stearate, etc., solubilizers such as nonionic surfactants, flavoring agents, sweeteners, stabilizers, pH adjusters, water, ethanol, propylene glycol, glycerin, etc. Also, coating agents such as hydroxymethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, methacrylate copolymers, etc. may be used.

[0018] The pharmaceutical composition of the present invention may also contain other active ingredients, such as vitamin B1: thiamine, thiamine nitrate, thiamine hydrochloride, fursultiamine, bisbentiamine, benfotiamine, thiamine disulfide, dicethiamine, thiamine propyl disulfide, and derivatives thereof, vitamin B2: riboflavin and derivatives and salts thereof, vitamin B3: niacin, nicotinic acid, nicotinamide and derivatives and salts thereof, vitamin B5: panthenol, pantothenic acid and derivatives and salts thereof, vitamin B6: pyridoxine and derivatives and salts thereof, vitamin B 12Cyanocobalamin and derivatives and their salts, other vitamins, vitamin A, vitamin C, vitamin E, vitamin K, vitamin P, diisopropylamine dichloroacetate, taurine, chondroitin sulfate, royal jelly, caffeine, turmeric, milk thistle, dandelion, burdock, garlic, chrysanthemum, yarrow, gardenia, sesame, Panax notoginseng, asparagus, onion, chicory, medicinal salvia, Korean thistle (artichoke), wolfberry, plants of the Fabaceae and Iridaceae families, quail, elba de passariño, sete sangria, Agametica, black tea, resveratrol, catechins, berberine, rosemary, bean extract, metformin, etc.

[0019] Furthermore, the composition of the present invention can be used not only as medicines, but also as functional foods such as quasi-drugs, foods for specified health uses, sports drinks, drinks for rehabilitation, and pet foods.

[0020] The content of the dipeptide in the pharmaceutical or food composition of the present invention varies depending on the administration form, but is usually preferably 0.001 to 10% by mass, more preferably 0.001 to 5% by mass. The daily dose of the dipeptide in the pharmaceutical or food composition of the present invention is preferably 10 mg to 1000 mg, more preferably 20 mg to 800 mg, and even more preferably 50 mg to 800 mg. EXAMPLES

[0021] The present invention will now be described in detail with reference to examples, but the present invention is not limited thereto in any way.

[0022] Example 1 (Fractionation of Liver Hydrolysate) (1) Fractionation of peptides and pyroglutamyl peptides Strong cation exchange resin (AG50) was packed in an Econo Column (2.5 x 20 cm), and the resin was equilibrated with 10 mM HCl. 1 g of liver hydrolysate (Sample A) was dissolved in 20 mL of 10 mM HCl. This solution was added onto the resin, and 20 mL of the non-flowing fraction was collected (non-flowing fraction 1). Next, 20 mL of 10 mM HCl was added onto the resin, and 20 mL of the non-flowing fraction was collected. This procedure was repeated 19 times (non-flowing fractions 2 to 20). The absorbance (230 nm) of non-flowing fractions 1 to 20 was measured, and the elution of peptides was confirmed. Next, 20 mL of 50% ammonia solution was added onto the resin, and 20 mL of the adsorbed fraction was collected. This procedure was repeated 20 times (adsorbed fractions 1 to 20). The absorbance (230 nm) of the adsorbed fractions 1 to 20 was measured, and the elution of the peptide was confirmed. The flow-through fraction (pyroglutamyl peptide fraction) and the adsorbed fraction (peptide fraction) were concentrated under reduced pressure using an evaporator.

[0023] (2) Hydrophilic and hydrophobic fractionation A solid-phase extraction column (Sep-Pak) was equilibrated with 10 mM HCl. The pyroglutamyl peptide fraction was passed through the column, and the flow-through fraction was eluted and collected (hydrophilic pyroglutamyl peptide fraction). Next, a 60% acetonitrile solution containing 10 mM HCl was passed through the column, and the adsorbed fraction was eluted and collected (hydrophobic pyroglutamyl peptide fraction). The peptide fraction was also subjected to these procedures. The four fractions obtained were freeze-dried.

[0024] Example 2 (1) Quantitative analysis of indigestible peptides in liver hydrolysates 1) 2.5 mg of liver hydrolysate was dissolved in 1 mL of 50 mM Tris-HCl. 2) Pancreatin (0.1 mg), leucine aminopeptidase (2.45 units), and carboxypeptidase (7.7 units) were added to 1) and the enzyme reaction was carried out (37°C, 24 hours). 3) The enzyme was removed by ultrafiltration (10K). 4) 3) was passed through a strong cation exchange resin (AG50) packed in a spin column, and the flow-through fraction was collected (pyroglutamyl peptide fraction). 5) 200 μL of 3) (peptide fraction) and 4) (pyroglutamyl peptide fraction) were fractionated and collected by size-exclusion HPLC (SEC Fr. 35-44). 6) For the peptide fraction, SEC Fr.35-44 was dried and converted to AccQ. For the pyroglutamyl peptide fraction, SEC Fr.35-44 was used as is. 7) The structures of the resistant peptides were determined by LC-MS / MS analysis. Column: Inertsil ODS-3 Eluent: 0.1% formic acid and 80% acetonitrile with 0.1% formic acid Analytical method: For the peptide fraction, the AccQ fragment (m / z=171.1) is specifically detected (precursor ion scan analysis), the structure is estimated by MS / MS analysis, and a standard is synthesized and identified and quantified by MRM analysis. For the pyroglutamyl peptide fraction, peaks are detected by total scan ion analysis, the structure is estimated by MS / MS analysis, and standards are synthesized and identified and quantified by MRM.

[0025] (2) Experiment on transfer of peptides into the bloodstream when liver hydrolysate was administered to rats 1) A single dose of liver hydrolysate solution (10g / 60kg) was administered to Wistar rats (6 weeks old, male). 2) 30 and 60 minutes after administration, blood was collected from the abdominal vena cava under isoflurane anesthesia to obtain plasma. The digestive tract (duodenum to ileum) was then removed and the luminal contents were eluted with 10 mL of physiological saline. Three volumes of ethanol were added to the plasma and digestive tract contents (stored at -20°C until analysis). 3) Plasma and digestive tract contents were dried over ethanol and converted to AccQ. 4) The indigestible peptides identified in (1) were identified and quantified by MRM analysis. The dipeptide concentrations in blood are shown in Table 1.

[0026] [Table 1]

[0027] As a result, it was found that (D)Asp-(D)Val, (D)Asp-(D)Phe, (D)Asp-(D)Ile, (D)Asp-(D)Leu, (D)Asp-(L)Val, (D)Asp-(L)Ile, (D)Asp-(L)Leu, and (D)Asp-(L)Phe have good transferability into the blood when orally administered and persist in the blood for a long period of time.

[0028] Example 3 (Synthesis of dipeptides) 1) Add the reagents to a recovery flask in the following order and react with stirring (4℃, overnight). (i)H-Leu-OtBu·HCl (ii) DMF (iii) TEA (iv) Boc-Asp(OtBu)-OH (Lα form) (v) HOBt (vi) EDL·HCl For other isomers, the following protected amino acids are used: Boc-D-Asp(OtBu)-OH (Dα form) Boc-Asp-OtBu (Lβ form) Boc-D-Asp-OtBu (Dβ form) 2) Remove the DMF using an evaporator. 3) Dissolve in ethyl acetate and transfer to a separatory funnel. 4) Add 5% sodium bicarbonate, stir, and remove the aqueous layer. (x2) 5) Add 10% citric acid, stir, and remove the aqueous layer. (x2) 6) Add saturated saline and stir, then remove the aqueous layer. 7) The ethyl acetate layer is collected and dehydrated by adding sodium hydrogen sulfate. 8) The ethyl acetate layer is collected by filtration and concentrated using an evaporator. 9) Add petroleum ether and dry the resulting precipitate. (If no precipitate forms, proceed to 10)) 10) Add 4M HCl / dioxane to the dried material and react with stirring (4℃, 24~48h). 11) Remove the 4M HCl / dioxane using an evaporator. 12) Diethyl ether is added, the resulting precipitate is ultrasonically crushed and washed, and the ethereal supernatant is removed with decane (x3). 13) Add diethyl ether and leave at 4°C overnight. 14) Diethyl ether is added, the resulting precipitate is ultrasonically crushed and washed, and the ethereal supernatant is removed with decane (x3). 15) Dry the precipitate.

[0029] Example 4 [Test Method] (1) Animals used For the experiment, ddY male mice (Japan SLC) weighing 28-32g (26g at time of delivery) were used, and were kept in a constant environment of 22±2℃, 55±5% humidity, and a 12-hour light / dark cycle (light period: 7:00-19:00, dark period: 19:00-7:00) until the experiment. The mice were kept in plastic cages (30cm length x 20cm width x 13cm height), and were allowed to consume solid food and tap water ad libitum except during the experiment. (2) Drugs used and preparation methods The hydrophobic peptide fraction, hydrophobic pyroglutamyl peptide fraction, hydrophilic peptide fraction, and hydrophilic pyroglutamyl peptide fraction were dissolved in saline and administered intraperitoneally (ip) at 0.1mL per 10g body weight. The administration schedule was as follows: before forced walking, saline or the hydrophobic peptide fraction, hydrophobic pyroglutamyl peptide fraction, hydrophilic peptide fraction, and hydrophilic pyroglutamyl peptide fraction were administered ip, and after 3 hours of forced walking, the animals were acclimated to the observation cage for 15 minutes, and then saline or the hydrophobic peptide fraction, hydrophobic pyroglutamyl peptide fraction, hydrophilic peptide fraction, and hydrophilic pyroglutamyl peptide fraction were administered ip. (3) Forced walking load For the forced walking challenge, the mice were placed in an electric rotating cage measuring 37 cm in diameter and 35.5 cm in depth, and forced to walk at a speed of 1 rotation per 25 seconds for 3 hours. (4) Measurement of spontaneous locomotion Spontaneous motor activity was evaluated by placing each mouse individually in a plastic cage (24 cm length × 17 cm width × 12 cm height) and allowing them to adapt to the environment for 15 minutes, after which the amount of planar motor activity was automatically quantified over a 90-minute period using a Supermex.

[0030] 〔result〕 The results are shown in Figures 1 to 4. As can be seen from Figures 1 to 4, the hydrophobic peptide fraction and the hydrophobic pyroglutamyl peptide fraction showed superior anti-fatigue effects compared to the hydrophilic peptide fraction.

[0031] Example 5 (1) Animals used For the experiment, ddY male mice (Japan SLC) weighing 28-32g (26g at time of delivery) were used, and were kept in a constant environment of 22±2℃, 55±5% humidity, and a 12-hour light / dark cycle (light period: 7:00-19:00, dark period: 19:00-7:00) until the experiment. The mice were kept in plastic cages (30cm length x 20cm width x 13cm height), and were allowed to consume solid food and tap water ad libitum except during the experiment. (2) Drugs used and preparation methods The dipeptides were dissolved in saline and administered intraperitoneally (ip) at 0.1 mL per 10 g body weight. The administration schedule was as follows: saline or dipeptide was administered ip before forced walking, and after 3 hours of forced walking, the animals were acclimated to the observation cage for 15 minutes, and then saline or dipeptide was administered ip. (3) Forced walking load For the forced walking challenge, the mice were placed in an electric rotating cage measuring 37 cm in diameter and 35.5 cm in depth, and forced to walk at a speed of 1 rotation per 25 seconds for 3 hours. (4) Measurement of spontaneous locomotion Spontaneous motor activity was evaluated by placing each mouse individually in a plastic cage (24 cm length × 17 cm width × 12 cm height) and allowing them to adapt to the environment for 15 minutes, after which the amount of planar motor activity was automatically quantified over a 90-minute period using a Supermex. (5) Statistical processing The experimental results were shown as the mean and standard error (SEM). Significant differences were tested by analysis of variance followed by Fisher's PLSD method. A P value of 5% or less was determined to be significant. Stat view-J 5.0 for Windows (registered trademark) was used for this test.

[0032] 〔result〕 The results are shown in Figures 5 to 10. As is clear from Figures 5 to 10, Asp-Leu (Dα form), Asp-Leu (Dβ form), Asp-Val (Dα form), Asp-Val (Dβ form), and (D)Asp-Phe (Dα, Dβ) showed excellent anti-fatigue effects.

Claims

1. An agent for preventing and improving fatigue, comprising a dipeptide selected from (D)Asp-(D)Leu, (D)Asp-(D)Val, (D)Asp-(D)Phe, (D)Asp-(L)Leu, (D)Asp-(L)Val, and (D)Asp-(L)Phe.

2. A food composition for preventing and improving fatigue, comprising a dipeptide selected from (D)Asp-(D)Leu, (D)Asp-(D)Val, (D)Asp-(D)Phe, (D)Asp-(L)Leu, (D)Asp-(L)Val, and (D)Asp-(L)Phe.

Citation Information

Patent Citations

  • JP1972031031U

  • JP1973000812B

  • Nutrition-supplying composition

    JP1994327435A

  • Enhancer for physical fitness

    JP1997124473A

  • Material for physical strength enhancement / recovery from fatigue, and food using the same

    JP2001046021A